Immune Thrombocytopenia (ITP) Clinical Trials

A listing of Immune Thrombocytopenia (ITP) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 59 clinical trials
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with low platelet count. As the first choice of the second-line treatment of ITP, thrombopoietin receptor agonist (TPO-RA

platelet count
eltrombopag
  • 1 views
  • 19 Jun, 2021
  • 1 location
Anti-BCMA CAR T-Cell Therapy for R/R ITP

This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy(BCMA CAR-T)for patients with relapse/refractory Immune thrombocytopenia(R/R ITP).

  • 0 views
  • 19 Apr, 2022
  • 1 location
A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)

This is a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/μL on two counts no sooner than 7 days apart in the 15 days before …

platelet count
thrombocytopenia
  • 16 views
  • 13 May, 2022
  • 28 locations
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)

This is a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients will receive rilzabrutinib or placebo 400mg …

platelet count
kidney function tests
neutrophil count
thrombocytopenia
igiv
  • 9 views
  • 27 May, 2022
  • 111 locations
A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)

This is a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/μL on two counts no sooner than 7 days apart in the 15 days before …

platelet count
thrombocytopenia
autoimmune thrombocytopenia
  • 455 views
  • 25 May, 2022
  • 28 locations
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)

This is a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients will receive rilzabrutinib or placebo 400mg …

platelet count
kidney function tests
neutrophil count
thrombocytopenia
igiv
  • 34 views
  • 05 Jun, 2022
  • 114 locations
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months

thrombocytopenia
avatrombopag
  • 13 views
  • 21 Jul, 2022
  • 55 locations
Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

The main purpose of this study is to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.

hemolysis
anemia
thrombocytopenia
  • 0 views
  • 23 Jul, 2022
  • 7 locations
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.

intravenous immunoglobulin
eltrombopag
autoimmune thrombocytopenia
immunoglobulins
thrombocytopenia
  • 10 views
  • 06 Feb, 2022
  • 11 locations
The DART Study- Daratumumab Treatment in ITP

A multicenter clinical, open-label total dose-escalating phase II study with safety run-in to explore the clinical activity, total dosage, and safety of daratumumab in adult ITP patients who have not responded adequately or relapsed after corticosteroids and at least one second-line therapy including rituximab and/or TPO-RA.

corticosteroids
steroid therapy
rituximab
platelet count
  • 8 views
  • 08 Jan, 2022
  • 4 locations